Transparent leadership

Independent board member Dr. Shore is Medical Director for the Carolina Urologic Research Center and is a Fellow of the American College of Surgeons. He has conducted more than 400 clinical trials focusing mainly on genitourinary oncology. Dr. Shore performs peer reviews for Lancet Oncology, New England Journal of Medicine, European Urology, the Journal of Urology, Urology, BJUI, PCPD, and other high-impact scientific journals. He serves on the executive boards of the Society of Urologic Oncology and the Bladder Cancer Advocacy Network (BCAN). He has served as the National/Global Urology Research Director for GenesisCare from 2019-2023. From 2016 to 2018 Dr. Shore was the President of the Large Urology Group Practice Association. In addition, he has served on  numerous Committees, Editorial and Review boards, such as the AUA Research and Innovations Committees, Health and Data Committees, the SITC Task Force for Prostate Cancer and Bladder Cancer, the Editorial Boards of Review in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, and the World Journal of Urology. Neal Shore holds no shares and 3 973 share options in Photocure.
He is an independent director, without material relationship with Photocure and being neither part of its executive team nor involved in the company’s day-to-day operations. 

• Chairperson of the Scientific Committee
• Advisor for ESG matters.

Dan Schneider joined Photocure November 2018. He brings more than 25 years of experience in developing and expanding rapidly growing healthcare companies in the U.S., most recently as the General Manager for Ablynx N.V. in North America. He has also held executive management positions in other pharmaceutical and biotech companies, including BTG International, Somaxon Pharmaceuticals and Sepracor. Mr. Schneider is a U.S. citizen and holds an MBA from Washington University and a Bachelor of Science degree in Business Administration from St. Louis University with a double major in Finance and Marketing. Dan Schneider holds 332,500 share options and 99,689 shares in the Company.

Erik Dahl, joined Photocure in August 2012 as CFO. He has more than 30 years of experience from senior level financial management roles, with responsibilities within corporate finance, legal and financial restructurings, M&A and capital market transactions. He has held various CFO roles in both public and private companies. Mr. Dahl has a Bachelor degree in finance and accounting from the Norwegian School of Economics. Erik Dahl holds 213,750 share options and 32,750 shares in the Company.

Geoff Coy joined Photocure in October 2019. He has nearly 25 years of experience in the life sciences industry including sales, marketing, sales operations and market access in the biopharmaceuticals and medical device areas. Prior to joining Photocure Geoff was the Commercial Vice President of Sales and Marketing for BTG International (Boston Scientific) where he lead strategic and operational business development. Prior to BTG Geoff has been in leadership roles for Sepracor Pharmaceuticals and GlaxoSmithKline. Geoff has a proven track record and ability to build and develop high-performing commercial teams that deliver results. Geoffrey Coy holds 216,250 share options and 15,207 shares in the Company.

Anders Neijber joined Photocure in August 2021, bringing over 25 years of substantial experience in the uro-oncology area and successful leadership in the pharmaceutical industry. He has had global and regional assignments, both in the U.S. and Europe, within Clinical R&D and Medical Affairs, having worked for Pfizer, AstraZeneca, Johnson & Johnson, Allergan and Ferring, where he held a similar global Medical Affairs leadership role as V.P., Global Therapeutic Area Head Uro-Oncology. Most recently he worked in Medical Affairs for Novartis in the Nordics. Anders completed his MD and PhD from Karolinska University, is a board certified urologist, and also holds an MBA. He held an assistant Professor position at the Department of Clinical Pharmacology, Robert Wood Johnson Medical School, New Jersey. Anders Neijber holds 114,000 share options in Photocure.

Susanne Strauss joined Photocure in July 2020 following Photocure's regaining worldwide rights to Hexvix® and the establishment of its own commercial operations in Europe. She brings over 20 years of international leadership experience in medical devices, life sciences and pharma, living and working across Europe and Asia with occasional remits in the U.S. Most recently Ms. Strauss held the position of General Manager of Asia Pacific for legacy BTG at Boston Scientific after leading BTG's Interventional Pulmonology Business as VP Commercial and expanding BTG's Interventional Oncology Business into Europe. Before that she worked in leadership positions for Convatec, Janssen-Cilag and Baxter. She holds a PhD in Technical Chemistry and an MBA from SDA Bocconi. Susanne Strauss holds 203,750 share options and 1392 shares in the Company.